Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Fibromyalgia treatment update

Rooks, Daniel S

Current Opinion in Rheumatology: March 2007 - Volume 19 - Issue 2 - p 111–117
doi: 10.1097/BOR.0b013e328040bffa
Epidemiology and health-related services

Purpose of review Fibromyalgia is a common chronic pain disorder characterized by complex symptomatology and few consistently effective treatments. The purpose of this review is to highlight the recent literature from April 2005 through September 2006 involving treatment options.

Recent findings Prior evidence suggests that medication and self-management approaches to care can improve symptoms, function and well-being in this patient population. Recent studies examining the efficacy of two serotonin and norepinephrine-reuptake inhibitors – duloxetine and milnacipran – and the anticonvulsant pregabalin are encouraging. Studies evaluating different forms of exercise continue to support the belief that increased physical activity is an essential component of any treatment plan for the patient with fibromyalgia. Three studies added to the understanding of treatment adherence. Finally, three studies evaluating the efficacy of acupuncture in the treatment of fibromyalgia showed conflicting results, but added to the knowledge needed for clinicians to have substantive conversations with patients.

Summary Recent studies support the recommendation of a multimodal approach to treatment involving individualized, evidence-based pharmacotherapy and self-management. Treatment goals should include the improvement of symptoms, primarily pain and sleep, and the promotion of positive health behaviors with the aim of improving physical function and emotional well-being.

Division of Rheumatology and the Center for the Study of Nutrition Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA

Correspondence to Daniel S. Rooks, PhD, FD 876, BIDMC, 330 Brookline Avenue, Boston, MA 02215, USA Tel: +1 617 667 2682; fax: +1 617 667 2608; e-mail:

© 2007 Lippincott Williams & Wilkins, Inc.